JP2017523149A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523149A5
JP2017523149A5 JP2016574064A JP2016574064A JP2017523149A5 JP 2017523149 A5 JP2017523149 A5 JP 2017523149A5 JP 2016574064 A JP2016574064 A JP 2016574064A JP 2016574064 A JP2016574064 A JP 2016574064A JP 2017523149 A5 JP2017523149 A5 JP 2017523149A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dosage form
composition according
edoxaban
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016574064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523149A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/060656 external-priority patent/WO2016020080A1/en
Publication of JP2017523149A publication Critical patent/JP2017523149A/ja
Publication of JP2017523149A5 publication Critical patent/JP2017523149A5/ja
Pending legal-status Critical Current

Links

JP2016574064A 2014-08-06 2015-05-13 エドキサバンの医薬組成物 Pending JP2017523149A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14180078.9 2014-08-06
EP14180078 2014-08-06
PCT/EP2015/060656 WO2016020080A1 (en) 2014-08-06 2015-05-13 Pharmaceutical compositions of edoxaban

Publications (2)

Publication Number Publication Date
JP2017523149A JP2017523149A (ja) 2017-08-17
JP2017523149A5 true JP2017523149A5 (enExample) 2018-06-21

Family

ID=53177487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574064A Pending JP2017523149A (ja) 2014-08-06 2015-05-13 エドキサバンの医薬組成物

Country Status (4)

Country Link
US (1) US20170231969A1 (enExample)
EP (1) EP3177290B1 (enExample)
JP (1) JP2017523149A (enExample)
WO (1) WO2016020080A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI826474B (zh) * 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
EP3744320A1 (en) 2019-05-29 2020-12-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising edoxaban
EP3838267A1 (en) * 2019-12-19 2021-06-23 Biohorm, S.L. Edoxaban tablets
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols
AU2023390819A1 (en) 2022-12-09 2025-07-03 Synthon B.V. Formulation comprising edoxaban and preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY155256A (en) * 2009-06-18 2015-09-30 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved solubility
CN102791271B (zh) * 2010-03-19 2014-05-14 第一三共株式会社 抗凝剂的溶出改善方法
WO2013026553A1 (en) * 2011-08-22 2013-02-28 Ratiopharm Gmbh Composition comprising edoxaban
US20130158069A1 (en) * 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment
CN103919746A (zh) * 2014-04-17 2014-07-16 山东省医药工业研究所 依度沙班缓释片及其制备方法

Similar Documents

Publication Publication Date Title
RU2016144479A (ru) Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости
JP2017523149A5 (enExample)
HRP20240564T1 (hr) Novi farmaceutski sastav
RU2017106795A (ru) Новые составы ингибитора тирозинкиназы брутона
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
JP2016147915A5 (enExample)
JP2015511635A5 (enExample)
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
SI2729130T1 (en) Combined formulations of darunavir
HRP20190069T1 (hr) Farmaceutske formulacije koje sadrže ccr3 antagoniste
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
JP2016508516A5 (enExample)
JP2016530238A5 (enExample)
EP3648745A4 (en) PHARMACEUTICAL COMPOSITION WITH SPHERICAL TABLET OF MULTIPLE UNITS WITH AMEOMEPRAZOLE AND SPHERICAL PHARMACEUTICAL SALT THEREOF AND METHOD FOR MANUFACTURING THE PHARMACEUTICAL COMPOSITION
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
JP2017520619A5 (enExample)
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
AU2016231883A1 (en) Pharmaceutical compositions of dimethyl fumarate
JP2015120758A5 (enExample)
WO2018108939A3 (de) Feste pharmazeutische orale darreichungsform mit verlängerter wirkstofffreisetzung umfassend mirabegron
EA201891646A1 (ru) Таблетки клозапина с замедленным высвобождением и способ их получения
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
JP2015221782A5 (enExample)
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.